Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

Fuwa M., Toris C.B., Fan S., Taniguchi T., Ichikawa M., Odani-Kawabata N., Iwamura R., Yoneda K., Matsugi T., Shams N.K., Zhang J.-Z.

2018
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

RandD Division, Santen Pharmaceutical Co. Ltd., 8916-16 Takayama-cho, Ikoma-shi Nara, 630-0101, Japan; Department of Ophthalmology, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, United States; Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, United States; RandD Division, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; RandD Division, Santen Inc., Emeryville, CA, United States

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications